- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Can J Infect Dis Med Microbiol. 2019 Dec 25;2019:6545642. doi: 10.1155/2019/6545642. eCollection 2019.
Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection.
Zhang ZQ1, Shi BS2, Lu W1, Liu DP1, Huang D1, Feng YL3.
Author information
1
Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
2
Scientific Research Center, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
3
Department of Clinical Pathology, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
Abstract
Background:
Changes of hepatitis B core antigen antibody (anti-HBc) in liver pathological involvement in patients with chronic hepatitis B virus (HBV) infection have not been investigated in detail. This study aimed to explore evolving patterns of anti-HBc following liver pathological states and to investigate validities of anti-HBc for predicting liver pathological states.
Methods:
254 HBeAg-positive and 237 HBeAg-negative patients with chronic HBV infection were enrolled. Liver pathological diagnoses referred to Scheuer standard, and anti-HBc was measured using chemiluminescence microparticle immunoassay.
Results:
Anti-HBc was significantly positively correlated with pathological grades and stages in both HBeAg-positive (r s = 0.312, P < 0.0001, and r s = 0.268, P < 0.0001) and HBeAg-negative (r s = 0.270, P < 0.0001, and r s = 0.147, P=0.0237) patients. The medians of anti-HBc in pathological grades of G1, G2, and G3 and stages of S1, S2, S3, and S4 in HBeAg-positive patients were all significantly lower than those in HBeAg-negative patients (all P < 0.005). The areas under receiver-operating characteristic curves (95% confidence interval) of anti-HBc for predicting pathological grades ≥G2 and ≥G3, and stages ≥S2 and =S4 in HBeAg-positive patients were 0.683 (0.622-0.740) and 0.662 (0.601-0.720), and 0.627 (0.564-0.687) and 0.683 (0.622-0.740), respectively, and in HBeAg-negative patients were 0.681 (0.618-0.740) and 0.702 (0.639-0.760), and 0.569 (0.503-0.633) and 0.630 (0.565-0.691), respectively.
Conclusion:
Following hepatic aggravation of necroinflammation and progression of fibrosis, anti-HBc increases gradually in HBeAg-positive patients and continues to increase gradually in HBeAg-negative patients, which is a useful but unsatisfactory marker for monitoring pathological states.
Copyright © 2019 Zhan-qing Zhang et al.
PMID:
31949546
PMCID:
PMC6948315
DOI:
10.1155/2019/6545642 |
|